MiniMed to Participate in Goldman Sachs 47th Annual Global Healthcare Conference
Rhea-AI Summary
MiniMed (Nasdaq: MMED) announced that its management will join a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference.
The session is scheduled for Monday, June 8, 2026, at 11:20 a.m. EDT, with a live webcast and replay available on the MiniMed investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – MMED
On the day this news was published, MMED declined 5.81%, reflecting a notable negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $194M from the company's valuation, bringing the market cap to $3.15B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 21 | Clinical outcomes update | Positive | +0.8% | Randomized trial showed strong glycemic outcomes across sensors with 780G. |
| Apr 13 | Earnings date set | Neutral | +5.7% | Announced schedule for Q4 and full-year 2026 financial results release. |
| Mar 18 | FDA device clearance | Positive | -0.2% | FDA cleared MiniMed Flex™, a smaller smartphone-controlled insulin pump. |
| Mar 09 | IPO completion | Positive | +1.8% | Closed IPO of 28,000,000 shares at $20.00, raising ~$538M in proceeds. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news with positive clinical or corporate developments often saw modestly positive price reactions, except for one FDA clearance that coincided with a slight decline.
Over the last few months, MiniMed has reported several key milestones. An IPO closed on Mar 6, 2026, raising about $538 million and leaving Medtronic with roughly 90.03% ownership. On Mar 18, 2026, the company announced FDA clearance of MiniMed Flex™, and a May 21, 2026 study showed strong glycemic outcomes with the 780G system. An upcoming earnings release on Jun 3, 2026 is scheduled. Today’s conference participation fits within this cadence of ongoing visibility events and product updates.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The fireside chat will take place on Monday, June 8, 2026, at 11:20 a.m. EDT.
A live webcast and replay will be accessible on the MiniMed Investor Relations website: investors.minimed.com/events.
About MiniMed
MiniMed is a global leader in insulin delivery, constantly advancing therapies that support people with diabetes in more than 80 countries. Our full-stack, integrated ecosystem, including our insulin delivery systems, CGMs, algorithms, and easy-to-use app experience, is designed to work seamlessly together, supported by white-glove, wrap-around service. For over 40 years, we've pioneered therapies people can rely on by anticipating needs, reducing burden, and helping make life with diabetes easier. Our mission is to make every day a better day for people with diabetes.
Any forward-looking statements are subject to risks and uncertainties such as those described in MiniMed's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.
View original content to download multimedia:https://www.prnewswire.com/news-releases/minimed-to-participate-in-goldman-sachs-47th-annual-global-healthcare-conference-302780816.html
SOURCE MiniMed